Wilsmann-Theis D, Kromer C, Gerdes S, et al. - In this phase 2 single-arm multicentre study (APLANTUS), researchers sought to investigate the effectiveness of apremilast, a phosphodiesterase 4 inhibitor that has been shown to be effective in the treatment of psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet’s disease, in palmoplantar pustulosis (PPP). In total, 21 patients were recruited and received treatment in five German dermatological centres beginning November 2018, of whom 20 patients finished the full course of interventions by August 2019. Apremilast was well tolerated in general, and no serious adverse events occurred. Patients with PPP who received apremilast showed improvements in both objective and subjective disease parameters. Apremilast should be studied further in this difficult-to-treat skin condition.